A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

This study has been completed.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00314158

Purpose

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Condition	Intervention	Phase
Open-Angle Glaucoma Ocular Hypertension	Drug: Brinzolamide 1%/Timolol 0.5%, Brinzolamide 1%, Timolol 0.5%	Phase III

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

Drug Information available for: Azopt Timolol Timolol maleate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Over 18 with open-angle glaucoma

Exclusion Criteria:

Under 18

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00314158

Locations

United States, Texas
United States Investigative Sites
Fort Worth, Texas, United States, 76134

Sponsors and Collaborators

Alcon Research

More Information

Study ID Numbers:	C-05-24
Study First Received:	April 10, 2006
Last Updated:	February 29, 2008
ClinicalTrials.gov Identifier:	NCT00314158
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Brinzolamide
Glaucoma
Eye Diseases
Glaucoma, Open-Angle

Vascular Diseases
Timolol
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Neurotransmitter Agents
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Enzyme Inhibitors
Cardiovascular Agents
Antihypertensive Agents

Pharmacologic Actions
Carbonic Anhydrase Inhibitors
Therapeutic Uses
Adrenergic beta-Antagonists
Cardiovascular Diseases
Adrenergic Antagonists
Anti-Arrhythmia Agents

ClinicalTrials.gov processed this record on January 16, 2009